# Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19

> **NCT04372082** · PHASE3 · WITHDRAWN · sponsor: **University Hospital, Lille**

## Conditions studied

- Sars-CoV2

## Interventions

- **OTHER:** Standard of care (SOC)
- **DRUG:** Hydroxychloroquine
- **DRUG:** Association of diltiazem and niclosamide

## Key facts

- **NCT ID:** NCT04372082
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05
- **Primary completion:** 2023-05
- **Final completion:** 2023-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** evidence showed chloroquine is not effective against COVID-19
- **Last updated:** 2021-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04372082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04372082, "Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04372082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*